Last reviewed · How we verify
ABBV-101
At a glance
| Generic name | ABBV-101 |
|---|---|
| Sponsor | AbbVie |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies (PHASE1)
- A Study to Assess How Food Affects the Movement of Oral ABBV-101 Through the Body of Healthy Adult Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ABBV-101 CI brief — competitive landscape report
- ABBV-101 updates RSS · CI watch RSS
- AbbVie portfolio CI